Equity
-€225,308
Debts exceed assets in financial year 2025.
272BIO
Lifetime
4 annual accounts with figures on one time axispeak €104,252 (2025)
€104,252▲ 490%
lowest -€631,558 (2025)
-€631,558▼ €174,349
peak €406,250 (2024)
-€225,308▼ €631,558
€934,909▼ 20.4%
peak 5.2 FTE (2025)
5.2 FTE▲ 48.6%
Board6 names since 2021
4 directors and 3 others
Owners
Documentsfilings and deeds
12-01-202619 days before the deadline
2025abbreviated format
Gross margin from €17,671 to €104,252Loss of €631,558Staff from 3.5 FTE to 5.2 FTEEquity from €406,250 to -€225,308Debts from €1.2m to €934,909Cash from €1.1m to €350,764
Key points
from the 2025 annual accountsLosses
-€1.4m in four years
Every financial year from 2022 to 2025 closed with a loss. 2025 was the heaviest.
Debts
€934,909 132% of the balance sheet
Suppliers 17%Taxes and wages 9%Other 75%
Of this, €855,742 falls due within a year.
Liquidity
0.50 was 1.08 in 2024
Short-term debts fell from €1.2m to €855,742.
At the same address
19 companies
Position in the sector
-€225,308
Less equity than 89% of companies in pharmaceuticals. Sector median €531,213 · 84 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 6,007 companies had the same profile as 272BIO has now. Each dot stands for 16 companies, two years later.
83.0%
were still trading
8.4%
stopped another way
7.9%
went bankrupt
Another 0.8% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 6,007 companies, not a prediction for 272BIO. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director, since 27-01-2021
Director, since 09-07-2024
Director, since 09-07-2024
Director, since 09-07-2024
- 100%annual accounts 30-06-2022
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0762638249
3 directors appointed
, and · General meeting of 09-07-2024 · Gazette deed
Registered office moved from Wommelgem to Zwijnaarde
Capital contribution of €1,200,000 · New registered office: Suzanne Tassierstraat 1, VIB BIOINCUBATOR, Unit 1.1, 9052 Zwijnaarde · Previous registered office: Nijverheidsstraat 70, 2160 Wommelgem · Gazette deed
Registered office moved within Wommelgem
New registered office: Nijverheidsstraat 70, 2160 Wommelgem · Previous registered office: Nijverheidsstraat 10, 2160 Wommelgem · Board meeting of 04-06-2021 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| 272BIO Ghent | €0.7m | €104,252 | -31.8% | 5.2 |
| Pharmentum Kontich | €1.2m | €40,883 | 25.9% | 1 |
| AnimAb Ghent | €3.5m | €28,596 | 79.6% | 5.6 |
| Flindr Labs Ghent | €0.3m | €294,811 | -148.7% | 4.2 |
| Dierenartsen Hond en Kat Deinze | €0.3m | €80,014 | 0.7% | - |
| OLYS Pharma La Hulpe | €1.0m | €158,424 | 56.0% | - |
| HEW PHARMA Kalmthout | €1.0m | €129,937 | 27.7% | - |
These companies have the same main activity as 272BIO: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201). They are comparable in size and age: total assets between €263,000 and €3.5m, founded between 2017 and 2024.
Official details
Source: KBO- Status
- Active since 28-01-2021Normal situation
- Registered office
- 20 active companies are registered at this address1 started in the 12 months before. Source: KBO register, as of 12 November 2026.
- Activity
- Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21201
- Joint committee
- 207White-collar workers in the chemical industry · annual accounts 30-06-2025
- Establishment unit
- 2.313.417.5349052 Ghent, since 28-01-2021
- Financial year end
- 30 June
- Peppol
- Reachable since 13-04-2026
Annual accounts to 30-06-2025
- ≈ €270,000estimated
- €709,601▼ 55.1%
- Employeeson 30-06-2025
- 6▲ 20.0%
- Filing
- Filed on 12-01-2026, 19 days before the end of the filing period
Insights on 272BIO
272BIO files the abbreviated format. That format states no turnover. The gross margin rose from -€18,400 in 2022 to €104,252 in 2025.
holds all the shares.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about 272BIO
- What is the company number of 272BIO?
- The company number of 272BIO is 0762.638.249. The VAT number is the same number with BE in front: BE 0762.638.249.
- Where is 272BIO based?
- The registered office is at Suzanne Tassierstraat 1, 9052 Ghent.Company details
- What does 272BIO do?
- According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201).
- What is the legal form of 272BIO?
- 272BIO is a private limited company (BV).
- When was 272BIO founded?
- 272BIO was founded on 28-01-2021.
- Is 272BIO still active?
- Yes, 272BIO is an active enterprise in the KBO register.
- How many employees does 272BIO have?
- 272BIO had an average of 5.2 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does 272BIO fall under?
- In its 30-06-2025 annual accounts, 272BIO states joint committee 207 (White-collar workers in the chemical industry).
- What is the turnover of 272BIO?
- The turnover in financial year 2025 is ≈ €270,000. This figure is estimated from the gross margin of €104,252 and 1,651 comparable companies of the same size. It probably lies between €160,000 and €490,000. It is a rough estimate.
- Is 272BIO profitable?
- In financial year 2025, 272BIO made a loss of €631,558.
- Where can I find the annual accounts of 272BIO?
- 272BIO filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of 272BIO due?
- 272BIO must file the annual accounts for financial year 2026 by 31-01-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.